Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2016-08-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
独立董事关于公司第二届董事会第三十二次会议相关议案之独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion statement from the independent directors of a company regarding specific matters discussed at a board meeting, including related party fund occupation, external guarantees, and the use of raised funds for the half-year period of 2016. It references compliance with laws and regulations and provides assurance on these matters. The document is short (1192 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is not a full audit report but rather an independent directors' opinion on certain financial and compliance issues related to the board meeting agenda. This fits best under Board/Management Information (MANG), as it relates to board meeting matters and independent directors' opinions on company affairs.
2016-08-18 Chinese
2016年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2016 半年度报告摘要' which translates to '2016 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes management discussion and analysis, shareholder information, and notes on accounting policies and changes. The content is comprehensive and includes actual financial statements and substantive financial data for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document length is 5798 characters, which is sufficient to be a report rather than a mere announcement. Therefore, the correct classification is IR with high confidence. H1 2016
2016-08-18 Chinese
第二届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 14th meeting of the second Supervisory Board of Kuaihua Pharmaceutical Group Co., Ltd. It includes approval of the company's 2016 semi-annual report and a special report on the use of raised funds. The text states that the Supervisory Board reviewed and approved the semi-annual report and the special report, confirming compliance with relevant regulations. The document is short (971 characters) and primarily serves as a meeting resolution announcement rather than containing the full semi-annual report or detailed financial data. Therefore, it is not the interim/quarterly report itself but an announcement related to it. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain full reports or detailed financial data.
2016-08-18 Chinese
2016年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2016 年半年度报告全文" which translates to "2016 Semi-Annual Report Full Text." It contains detailed financial data, management discussion, business analysis, investment status, and other comprehensive information for the half-year period ending June 30, 2016. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification, and the content is consistent with a full interim report rather than a brief summary or announcement. Therefore, the correct classification is IR with high confidence. H1 2016
2016-08-18 Chinese
关于葵花药业集团重庆小葵花健康产业发展有限公司领取营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the establishment and registration of a wholly-owned subsidiary, including details about the business license, company name, legal representative, registered capital, and business scope. It does not contain financial statements, audit information, or regulatory filings related to financial performance. It is not a report, earnings release, or management discussion. The content fits the category of a general regulatory announcement about corporate structure and business registration, which aligns with Regulatory Filings (RNS). The document length is short and it is an announcement rather than a detailed report.
2016-08-16 Chinese
关于更换保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the sponsor representative for the company's initial public offering (IPO) project. It mentions the replacement of a sponsor representative due to resignation and the appointment of a new one to continue the supervision work. There is no financial data, report, or detailed analysis present. The document is a formal announcement about management/sponsor changes related to the IPO process, which fits best under Board/Management Information (MANG). The document length is short and it is not a report or financial statement, so it is not an Annual Report or Interim Report. It is not a regulatory filing or report publication announcement since it contains substantive information about management changes.
2016-08-08 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.